APOH and atherosclerosis: Antiphospholipid antibodies (aPL), that are anticardiolipin antibodies (aCL) and anti-β2-glycoprotein I antibodies (anti-β2GPI), can contribute to accelerated atherosclerosis by inducing a proinflammatory endothelial phenotype through a direct interaction with ECs (41).